Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 14/20 | 0.71 |
| ▸ | KDR | P35968 | 14/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.71 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.71 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.69 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.69 |
| ▸ | FLT3 | P36888 | 4/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.59 |
| ▸ | MET | P08581 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 3/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672549 | 1.00 | PDGFRB (0.71) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2114525 | 0.96 | PDGFRB (0.69) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL13755251 | 0.94 | KDR (0.78) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2118618 | 0.91 | PDGFRB (0.67) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672448 | 0.91 | PDGFRB (0.67) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL13755266 | 0.89 | KDR (0.64) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2116220 | 0.89 | PDGFRB (0.73) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2115759 | 0.89 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672414 | 0.89 | KDR (0.73) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672513 | 0.89 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | PDGFRB 40/4885KDR 648/4885FGFR1 48/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | PDGFRB 1034/4885KDR 1387/4885FGFR1 1227/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | PDGFRB 555/4885KDR 395/4885FGFR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.